Wednesday, June 10, 2026
πŸ‡ΊπŸ‡Έ FDA

pharma Β· Inflammatory Bowel Disease (IBD) Β· Melanoma Β· IRON

Disc Medicine

Disc Medicine trial registry β€” 309 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
321 Arsenal St., Suite 101, Watertown, Massachusetts 02472-5710, US HQ
165 Employees
Public company Type
IRON Β· NYSE Ticker
Company details
Status
Public
HQ
321 Arsenal St., Suite 101, Watertown, Massachusetts 02472-5710, US
Employees
165
Programs
308
Drugs
442
Patents
706
Official website β†— All projects Drug pipeline Patents News & analysis
Intelligence Β· Clinical Trials

Disc Medicine clinical trials

Registry index of 309 ClinicalTrials.gov studies linked to Disc Medicine programs β€” each row shows trial ID, program name, phase, status, and indication.

Disc Medicine trial registry β€” 309 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Disc Medicine.

  1. NL77785.078.21 β€” Approved

    Clinical update

  2. Sodium Chloride Fresenius Kabi Italia 0.9 % S... β€” Approved

    Clinical update

  3. Sodium Chloride 0.9% for Vulvar High-Grade Squamous Intr… β€” Approved

    Clinical update

  4. 202100617 β€” Phase 3

    Clinical update

  5. 17651 β€” Phase 1

    Clinical update

  6. UMCG-NEOLYNC-001 β€” Phase 1

    Clinical update

  7. TIL in NSCLC β€” Phase 1

    Clinical update

  8. RT2019-13 β€” Phase 3

    Clinical update

Trial registry

309 studies
  4. 2023-504880-18-00

    CRISP ITCC-053

    Phase 2 active small_molecule

    Neuroblastoma (NBL), Rhabdomyosarcoma (RMS), Inflammatory Myofibroblastic Tumors (IMT), Other ALK/ROS1/MET-positive malignancies, Anaplastic Large Cell Lymphoma (ALCL)

    CTIS β†—
  27. 2023-508389-13-00

    202100617

    Phase 3 active small_molecule

    Combined endpoint of all-cause mortality, kidney failure, and hospitalization for heart failure in the overall study population

    CTIS β†—
  37. 2023-509210-10-00

    NL85300.041.23

    Phase 1 active other

    Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment.

    CTIS β†—
  41. 2023-509675-16-01

    HEPARIN , NADROPARIN

    Phase 3 active small_molecule

    All patients who receive ECMO treatment during the study period in one the participating centers from which (deferred) informed consent is obtained. Patients in whom the ECMO is only used to bridge a procedure like a high risk percutaneous coronary intervention or during surgery are excluded.

    CTIS β†—
  45. 2023-510488-36-01

    18870

    Phase 2 active small_molecule

    Chronic obstructive pulmonary disease (COPD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and atypical Parkinson disorder (APD), particularly multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS).

    CTIS β†—
  90. 2024-513041-37-00

    18-791

    Phase 3 active small_molecule

    Brain injury in neonates with critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass.

    CTIS β†—
  93. 2024-513124-41-00

    NL79088.041.21

    Phase 3 active small_molecule

    Primary antibody deficiency: - Unclassified antibody deficiency (unPAD) - IgA deficiency - Specific polysaccharide antibody deficiency (SPAD) - IgG subclass deficiency (IgSD) - Common variable immunodeficiency (CVID) - Agammaglobulinemia (X-linked or otherwise)

    CTIS β†—
  187. 2024-516795-15-00

    202000570

    Phase 2 active small_molecule

    Metastatic solid tumors, these may include but are not limited to melanoma, non-small-cell lung carcinoma (NSCLC), cervical cancer, microsatellite instable (MSI)-high/deficient mismatch repair (dMMR) cancer, renal cell carcinoma (RCC), CSCC, urothelial cell carcer (UCC), small cell lung cancer (SCLC) and head and neck squamous cell carcinoma (HNSCC).

    CTIS β†—
  230. 2024-518769-80-00

    NL6220204217

    Approved active small_molecule

    HAMLETT compares regular treatment guidelines for patients in remission after a first episode of psychosis, namely continuation with antipsychotic medication for at least one year, with early dose reduction/discontinuation.

    CTIS β†—
  253. 2025-520792-67-00

    DIDaC/ NVALT35

    Phase 3 active small_molecule

    Patients with advanced, metastatic NSCLC that have not progressed on a standard of care immunotherapy regimen 6 months after initiation of first line treatment.

    CTIS β†—

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.